Recent studies suggest that targeting Delta-like protein (DLL3), a direct transcriptional target of ASCL1, may yield promising results, with SCLC-A patients potentially showing greater responsiveness [20]. This evidence concerns the gene ASCL1 and small cell lung carcinoma.